Anticipated $0.48 EPS for Ligand Pharmaceuticals Incorporated (LGND) as of May, 8

April 16, 2018 - By Mark Mitchell

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Corporate Logo
Big Money Sentiment decreased to 1.25 in 2017 Q4. It has change of 0.44, from 2017Q3’s 1.69. The ratio turned negative due to Ligand Pharmaceuticals Incorporated positioning: 21 sold and 86 reduced. 31 funds bought positions and 103 increased positions. Investors holded 22.76 million in 2017Q3 but now own 22.68 million shares or 0.37% less.
Gemmer Asset Management Ltd Liability holds 0% or 53 shs. Tocqueville Asset Mngmt Limited Partnership has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). 22,430 were reported by Timpani Mgmt Limited Com. Tci Wealth Advisors reported 18 shs. Virginia Retirement Et Al reported 0.01% stake. Gamco Investors Et Al reported 6,000 shs. Falcon Point Cap Limited Liability Co holds 2.23% or 96,429 shs. Jpmorgan Chase holds 0% or 43,142 shs in its capital. Suntrust Banks Inc has 2,093 shs. Next Century Growth Limited Liability Company invested in 1.42% or 83,612 shs. Stephens Mngmt Limited Liability Company owns 429,734 shs or 1.34% of their US capital. Cypress Cap Lc (Wy) stated it has 15 shs. Renaissance Technologies Ltd Liability Co reported 49,400 shs. Eqis Capital Mngmt Incorporated holds 0.06% or 8,484 shs. Manufacturers Life Insur The holds 0% or 15,588 shs in its capital.

Ligand Pharmaceuticals Incorporated had 12 insider sales and 0 insider purchases since December 20, 2017. This’s net activity of $16.28 million. KOZARICH JOHN W also sold $401,063 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shs. 5,444 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shs with value of $832,824 were sold by FOEHR MATTHEW W. Sabba Stephen L sold $112,414 worth of stock. The insider HIGGINS JOHN L sold 28,099 shs worth $4.32M. On Thursday, March 8 Aryeh Jason sold $1.32 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) or 7,500 shs. 17,170 shs were sold by Davis Todd C, worth $2.62M.

On May, 8. Investors wait Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to reveal its quarterly earnings, Zacks reports. Last year’s earnings per share was $0.39, while now analysts expect change of 23.08 % up from current $0.48 earnings per share. If reported the P/E will be 87.32 with $10.18 million profit. -53.40 % negative EPS growth is what Wall Street’s sees after $1.03 reported EPS last quarter. The stock increased 1.20% or $1.98 during the last trading session, reaching $167.65.Ligand Pharmaceuticals Incorporated has volume of 138,152 shares. Since April 17, 2017 LGND has risen 53.11% and is uptrending. The stock outperformed the S&P 500 by 41.56%.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

Total analysts of 5 have positions in Ligand Pharma (NASDAQ:LGND) as follows: 4 rated it a “Buy”, 1 with “Sell” and 0 with “Hold”. The positive are 80%. Since October 18, 2017 according to StockzIntelligence Inc Ligand Pharma has 11 analyst reports. On Thursday, February 22 Craig Hallum maintained the shares of LGND in report with “Buy” rating. On Monday, November 13 the company was maintained by Roth Capital. In Thursday, November 9 report H.C. Wainwright maintained it with “Buy” rating and $159 target. On Wednesday, October 18 the rating was maintained by H.C. Wainwright with “Buy”. In Monday, February 26 report Roth Capital maintained the stock with “Buy” rating. On Wednesday, March 7 the firm has “Buy” rating by Craig Hallum given. On Wednesday, January 24 the stock has “Buy” rating by H.C. Wainwright. The stock rating was maintained by H.C. Wainwright with “Buy” on Wednesday, March 7. On Thursday, February 22 Stephens maintained the shares of LGND in report with “Buy” rating. On Wednesday, November 15 the stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Buy” rating given by Craig Hallum.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.The firm is worth $3.56 billion. The Company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer.The P/E ratio is 316.32. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.